Resuscitation Equipment (Global Market)

Chronicle

2024:6% market growth to $2.4 billion

In 2024, sales of resuscitation equipment on a global scale amounted to $2.4 billion in monetary terms. This corresponds to an increase of 6% compared to the previous year, when the market size was estimated at $2.26 billion. Such data are reflected in the Market Research Future study, the results of which were published at the end of February 2025.

The demand for resuscitation equipment is growing steadily worldwide, driven by an aging population and an increase in the prevalence of chronic diseases. Ailments such as high blood pressure, obesity and diabetes lead to a spike in the number of cardiac arrests, which requires effective resuscitation procedures. There is an increase in demand for automatic external defibrillators - portable devices that independently diagnose some heart rhythm disorders and can automatically perform defibrillation.

Technological advances have a positive impact on the market. Modern devices provide improved efficiency and reliability, which increases the likelihood of survival of patients after cardiac arrest. A shift towards more compact and user-friendly resuscitation devices, which can be used outside of traditional medical institutions, is recorded. The integration of artificial intelligence expands the functionality of equipment. AI algorithms help optimize care processes, so resuscitation devices can be used even by non-specialists. In addition, there is an active development of special training programs for emergency assistance.

Analysts note that the market is characterized by rapid advances in technology and a growing focus on emergency health services. Large companies are investing heavily in research and development to create devices equipped with advanced features that can improve patient outcomes in a wide variety of situations. Significant players in the industry in question are:

• Becker Orthopedic;
• Zoll Medical Corporation;
• Nihon Kohden;
• BristolMyers Squibb;
• PhysioControl;
• Laerdal Medical;
• Stryker Corporation;
• GE Healthcare;
• Lifestat;
• Philips Healthcare;
• Cardiac Science Corporation;
• Ambu A/S;
• Schiller AG;
• Medtronic;
• EpiPen.

Four main market segments stand out: manual defibrillators, automatic external defibrillators, equipment for advanced resuscitation measures and respiratory control devices. In 2024, products of the first type brought in revenues of about $0.6 billion. The largest contribution to the total market volume was provided by automatic external defibrillators - approximately $0.9 billion. The equipment of the other two categories accounted for $0.7 billion and $0.2 billion, respectively. Geographically, North America is leading with an estimate of $1.1 billion: the dominance of the region is due to the developed health infrastructure and high demand for emergency medical services. Europe is in second place with costs of $0.8 billion, and Asia-Pacific closes the top three with $0.4 billion. The contribution of South America amounted to $0.05 billion, the same amount fell on the Middle East and Africa.

In the future, analysts at Market Research Future believe that the industry will demonstrate sustainable development. The compound percentage CAGR is expected to be 5.89%. As a result, by 2035, costs could rise to $4.5 billion.^[1]

Notes